Tenidap Inhibits Phospholipase A Synthesis in Rat Osteoblasts
Author Information
Author(s): W. Pruzanski, B. P. Kennedy, H. van den Bosch, E. Stefanski, M. Wloch, P. Vadas
Primary Institution: University of Toronto
Hypothesis
Does Tenidap inhibit the synthesis of secretory non-pancreatic phospholipase A2 in foetal rat calvarial osteoblasts?
Conclusion
Tenidap significantly inhibits the synthesis of phospholipase A2 in foetal rat calvarial osteoblasts.
Supporting Evidence
- Tenidap reduced sPLA2 release by 40% at a concentration of 0.25 µg/ml.
- At 2.5 µg/ml, Tenidap reduced sPLA2 activity by over 80%.
- Immunoblotting showed a dose-dependent reduction in sPLA enzyme levels.
Takeaway
Tenidap is a medicine that helps reduce inflammation by stopping certain proteins from being made in the body.
Methodology
The study used foetal rat calvarial osteoblasts to assess the effect of Tenidap on phospholipase A2 synthesis through various concentrations and stimulation with IL-1 and TNF.
Limitations
The study was conducted in vitro, and results may not fully translate to in vivo conditions.
Participant Demographics
Foetal rat calvarial osteoblasts were used in the study.
Statistical Information
P-Value
p<0.01
Statistical Significance
p<0.01
Want to read the original?
Access the complete publication on the publisher's website